No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture
At present, neither a selective antiviral therapy nor a vaccine is available for HCV, and the current treatment is only effective in a fraction of patients. Given the recent demonstration that antiviral compounds targeting the NS5B polymerase and the NS3/4A protease lead to rapid selection for resis...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2010
|
| _version_ | 1797094786811822080 |
|---|---|
| author | Steinmann, E Friesland, M Ciesek, S Zitzmann, N Pietschmann, T |
| author_facet | Steinmann, E Friesland, M Ciesek, S Zitzmann, N Pietschmann, T |
| author_sort | Steinmann, E |
| collection | OXFORD |
| description | At present, neither a selective antiviral therapy nor a vaccine is available for HCV, and the current treatment is only effective in a fraction of patients. Given the recent demonstration that antiviral compounds targeting the NS5B polymerase and the NS3/4A protease lead to rapid selection for resistance, iminosugar derivatives as HCV assembly inhibitors were characterized for drug resistance. It has been previously shown that deoxynojirimycin (DNJ)-containing iminosugars are potent HCV antivirals inhibiting ER alpha-glucosidases I and II. Long alkyl chain derivatives such asNN-DGJ inhibit the HCV p7 ion channel activityin vitro. The aim of this study was to characterize the drug resistance profile of an inhibitor targeting cellular enzymes (NB-DNJ) and of the p7 inhibitor NN-DGJ in comparison to the NS5B polymerase inhibitor 2’C-methyladenosine (2CMA). |
| first_indexed | 2024-03-07T04:18:49Z |
| format | Journal article |
| id | oxford-uuid:ca51c17f-8eb1-473e-bd27-7bf46cd1b6c7 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T04:18:49Z |
| publishDate | 2010 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:ca51c17f-8eb1-473e-bd27-7bf46cd1b6c72022-03-27T07:06:31ZNo evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue cultureJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ca51c17f-8eb1-473e-bd27-7bf46cd1b6c7Symplectic Elements at OxfordElsevier2010Steinmann, EFriesland, MCiesek, SZitzmann, NPietschmann, TAt present, neither a selective antiviral therapy nor a vaccine is available for HCV, and the current treatment is only effective in a fraction of patients. Given the recent demonstration that antiviral compounds targeting the NS5B polymerase and the NS3/4A protease lead to rapid selection for resistance, iminosugar derivatives as HCV assembly inhibitors were characterized for drug resistance. It has been previously shown that deoxynojirimycin (DNJ)-containing iminosugars are potent HCV antivirals inhibiting ER alpha-glucosidases I and II. Long alkyl chain derivatives such asNN-DGJ inhibit the HCV p7 ion channel activityin vitro. The aim of this study was to characterize the drug resistance profile of an inhibitor targeting cellular enzymes (NB-DNJ) and of the p7 inhibitor NN-DGJ in comparison to the NS5B polymerase inhibitor 2’C-methyladenosine (2CMA). |
| spellingShingle | Steinmann, E Friesland, M Ciesek, S Zitzmann, N Pietschmann, T No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture |
| title | No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture |
| title_full | No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture |
| title_fullStr | No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture |
| title_full_unstemmed | No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture |
| title_short | No evidence for drug resistance by iminosugar-based HCV assembly inhibitors in tissue culture |
| title_sort | no evidence for drug resistance by iminosugar based hcv assembly inhibitors in tissue culture |
| work_keys_str_mv | AT steinmanne noevidencefordrugresistancebyiminosugarbasedhcvassemblyinhibitorsintissueculture AT frieslandm noevidencefordrugresistancebyiminosugarbasedhcvassemblyinhibitorsintissueculture AT cieseks noevidencefordrugresistancebyiminosugarbasedhcvassemblyinhibitorsintissueculture AT zitzmannn noevidencefordrugresistancebyiminosugarbasedhcvassemblyinhibitorsintissueculture AT pietschmannt noevidencefordrugresistancebyiminosugarbasedhcvassemblyinhibitorsintissueculture |